Natto: Rudi De Man Named VP Sales & Business Development of NattoPharma ASA

OSLO, NORWAY – (May 20, 2015)  Rudi De Man has been appointed Vice President of Sales and Business Development of NattoPharma ASA, responsible for Europe and Asia.

“NattoPharma ASA recognizes that the European and Asian markets pose a huge growth potential for our science-based MenaQ7 Vitamin K2 as MK-7,” says Frode M. Bohan, Chairman of the Board of NattoPharma ASA, Høvik, Norway. “This opportunity requires a dedicated hand, which is why we have added Rudi De Man to our global management team. He brings a deep understanding of these markets from his nutraceutical and food ingredients background, reinforcing NattoPharma’s great expectations for the future.”

Prior to joining NattoPharma, De Man held sales leadership and business development roles where he was directly responsible for driving record growth in the FMC Health and Nutrition division, a $900M group within FMC Corporation, a $4 billion diversified chemical company. During his 19-year tenure at FMC, De Man served in a variety of sales roles with increasing responsibility, acquiring international sales experience and an extensive knowledge of the Food Ingredients and Pharmaceutical & Nutraceutical business. His most recent position was Sales Director Europe, Middle East, Africa, and Eastern Europe for Food Stabilizers and Colors, where he was responsible for managing the Food and Personal Care business. Further, with a degree in Biochemistry and as a Chemical Engineer, De Man played an integral role at a leading European starch producer developing a new range of more performant drilling starches, while setting up a network of distributors in Asia.

De Man has achieved proven successes maintaining relationships and acquiring new business through a thorough understanding of his company’s technologies, and how they could benefit his customers,” says Hogne Vik, NattoPharma CEO. "With an extensive knowledge of the nutraceutical and pharmaceutical industries, we are confident he will be an engaging member of our global management team, guiding our current and potential partners on a mutually profitable path to create innovative products that take full advantage of our clinically validated MenaQ7 Vitamin K2 as MK-7.”

Reporting to NattoPharma COO Daniel H. Rosenbaum, De Man will be responsible for driving sales in Europe and Asia, while growing awareness of MenaQ7®. He will provide technical expertise to regional partners and key accounts, identifying and developing opportunities to leverage existing proprietary MenaQ7 Vitamin K2 science and technology, and directly contributing to the company’s global strategy and growth intiatives.

# # #

About MenaQ7®

MenaQ7® provides natural vitamin K2 as a manufactured fermentation extract. This process generates a highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the purest vitamin K2 on the market. MenaQ7 is the only vitamin K2 with proven positive clinical health effects on bones and the cardiovascular system. MenaQ7 vitamin K2 is the only vitamin K2 supported by several granted patents on cardiovascular health worldwide.

About NattoPharma

As a biotechnology and nutraceutical company, NattoPharma is the worldwide pioneer and innovator for developing, documenting and provide Vitamin K2 menaquinone-7 . Its brand MenaQ7® is supported by a global IPR portfolio and research substantiating clear positive clinical efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in a research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:

Hogne Vik,

CEO (+47-97535326


Kate Quackenbush

Director of Communications

(609) 643-0748


About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.